Cellastra Revenue

About Cellastra

ENCODING SCARLESS HEALING TARGETING UNMED NEEDS IN RESPIRATORY INFECTIONS/COVID-19, WOMEN'S HEALTH, AESTHETIC SUFRGERY & BURN CARE Cellastra Inc., a developer of disruptive gene therapies, is a private biotech company based in the San Francisco Financial District. It was founded and managed by proven industry executives with a track record of execution. Cellastra’s mission is to develop Disruptive, First or Best in Class Gene Therapies. Cellastra Proprietary Technology - Gene Vector- Anti-scarring peptide: Cellastra is developing viral gene vector-mediated intervention to address an area of great unmet medical needs in scarless wound healing after surgery and respiratory infections: 1. Surgery: Prevent excessive dermal scarring, e.g., after breast augmentation surgery, and C section. 2. Respiratory Infections: Prevent an excessive immune response, tissue damage, and scarring/fibrosis in high-risk patient groups with respiratory infections such as COVID-19 (coronavirus disease 2019) and RSV (respiratory syncytial virus). Scarless wound healing can be achieved by using a gene vector encoding for endogenous continuous production of the anti-scarring peptides at the site of injury. Thus, two gene vectors are planned for development (Cellexa applied under the skin after surgery and Virexa inhaled into the lungs in COVID-19 and other respiratory infections). The development of these vectors is built and expands upon a foundation of scientific proof of concept data of the anti-scarring peptide ensereptide.For more information see link to website,

View contact profiles from Cellastra